Studies on condensed 1,4-dihydropyridine derivatives and their calcium modulatory activities

Pharmazie

Volumn 61, Issue 8, 2006, Pages 655-659

  Aydin, F ^a   Şafak, Cihat ^a   Simsek R ^a   Erol, K ^b   Ulgen M ^c   Linden, A ^d  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; ALDEHYDE DERIVATIVE; BENZYLIDENE DERIVATIVE; BROMIDE; CYCLOHEXANONE; CYCLOHEXENE DERIVATIVE; ESTER; FUROQUINOLINE DERIVATIVE; HEXAHYDROQUINOLONE DERIVATIVE; PYRIDINE; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CHEMICAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; BIOTRANSFORMATION; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROPYRIDINES; FEMALE; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROSOMES, LIVER; MODELS, MOLECULAR; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; QUINOLONES; RATS; SHEEP; SPECTROPHOTOMETRY, INFRARED; X-RAY DIFFRACTION;

EID: 33748085003     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Altaş Y, Şafak C, Batu OS, Erol K (1999) Studies on calcium modulatory activities 2,6,6-trimethyl-3-ccetyl-4-aryl-5-oxo-1,4,5,6,7,8- hexahydroquinoline derivatives. Arzneim Forsch Drug Res 49: 824-829.
2. Fieser LF, Fieser M (1967) In Reagents for Organic Chemistry, JohnWilley, NewYork.
3. Franckowiak G, Bechem M, Schramm M (1985) The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on ca channels. Eur J Pharmacol 114: 223-226.
4. Godfraind T, Miller R, Wibo M (1986) Calcium antagonism and calcium entry blockade. Pharmacol Rev 38: 321-329.
5. Guengerich FE, Peterson LA, Böcker RH (1988) Cytochrome P-450-catalyzed hyydroxlation and carboxylic ester cleavage of Hantzsch esters. J Biol Chem 263: 8176-8183.
6. Hantzsch A (1882) Justus Liebigs Ann Chem 215: 1-15.
7. 2+ channel antagonists and activators: A comparison of binding characteristics with pharmacology. Drug Develop Res 4: 257-274.
8. 2+ channel antagonists. J Med Chem Med Chem 26: 775-785.
9. Kazda S, Garthoff B, Meyer H, Schlossmann K, Stoepel K, Towart R, Vater W, Wehinger E (1980) Pharmacology of a new calcium antagonistic compound, isobutyl methyl-1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5- pyridinedicarboxylate. Arzneim Forsch Drug Res 30: 2144-2162.
10. Langs DA, Triggle DJ (1985) Conformational features of calcium channel agonist and antagonist analogs of nifedipine. Mol Pharmacol 27: 544-548.
11. Linden A, Şafak C, Şimşek, R (1998) Racemic ethyl 4-(2-fluorophenyl)-2,6,6-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3- carboxylate. Acta Crystallogr C 54: 879-882.
12. Rose U (1989) Kalzium-modulatoren von Typ anellierter Dihydropyridine. Synthese und pharmakologische Wirkung. Arzneim Forsch Drug Res 39: 1393-1398.
13. Rose U (1990a) 5-Oxo-1,4-dihydroindenopyridines: Calcium modulators with partial calcium agonistic activity. J Heterocycl Chem 27: 237-242.
14. Rose U (1990b) Hexahydrochinolinone mit calciummodulatorischem Effekt. Synthese und pharmakologische Wirkung. Arch Pharm 323: 281-286.
15. Rose U (1991) Synthesis and pharmacological activities of calcium modulatory hexahydro-quinolines. Arzneim Forsch Drug Res 41: 199-203.
16. Rovnyak GC, Kimball SD, Beyer B, Cucinotta G, DiMarco JD, Gouguotas J, Hedberg A, Malley M, McCarthy JP, Zhang R et al. (1995) Calcium entry blockers and activator: Conformational and structural determinants of dihydropyrimidine calcium channel modulators. J Med Chem 38: 119-129.
17. Şafak C, Erdemli E, Sunal R (1993) Synthesis of some 1,4,5,6,7,8-hexahydroquinoline derivatives and their calcium antagonistic activities. Arzneim Forsch Drug Res 43: 1052-1055.
18. Şafak C, Özkanli F, Erol K, Aktan Y (1995) 3-Acetyl-4-aryl-5-oxo-2,7,7-trimethyl-1,4,5,6,7,8-hexahydroquinoline derivatives and their calcium antagonistic activities. Arzneim Forsch Drug Res 45: 1154-1156.
19. Şimşek R, Linden A, Şafak C (2000) (±)-9-(2-Bromophenyl)-7,7-dimethyl-1,3,4,5,6,7,8,9-octahydrofuro[3,4-b] quinoline-1,8-dione. Acta Crystallogr C 56: 351-353.
20. Ulgen M (1992) PhD Thesis, University of London, King's College, London.
21. Weiner DA (1988) Calcium channel blockers. Med Clin North America 72: 83-115.